Friday, June 3, 2022

Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers reported.

from Latest Science News -- ScienceDaily https://ift.tt/0LH9PVY
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Scientists say most people need more protein than current guidelines suggest

A new review suggests that doing more exercise and eating more protein than current minimum recommendations may help people stay stronger, s...